Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Yulia A. Chabaeva"'
Autor:
Olga A. Aleshina, Kristina Zakurdaeva, Anastasia N. Vasileva, Sergey K. Dubov, Vitaly S. Dubov, Vladimir I. Vorobyev, Lev S. Butaev, Alena M. Sukhareva, Lubov V. Gavrilova, Inessa Yu. Toropova, Marina O. Popova, Aleksandr A. Siniaev, Aleksandr D. Kulagin, Kamil D. Kaplanov, Andrei A. Petrenko, Oksana I. Ochirova, Alina Karpova, Ekaterina Yu. Chelysheva, Anna G. Turkina, Margarita A. Gurianova, Liubov S. Al-Radi, Elena A. Gilyazitdinova, Elena K. Egorova, Yulia A. Chabaeva, Sergey M. Kulikov, Yulia V. Sveshnikova, Mikhail A. Kunst, Vasily Shuvaev, Anzhelika F. Rakhmani, Olga L. Panteleeva, Maria E. Grishunina, Olga S. Samoylova, Ekaterina Vorontsova, Daria V. Baryshnikova, Elena N. Parovichnikova
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia.
Autor:
Sergey Dubov, Valery G. Savchenko, Lev S. Butaev, Hunan Julhakyan, Yulia Sveshnikova, Inessa Yu. Toropova, Oksana Ochirova, Olga A. Gavrilina, E A Gilyazitdinova, Aleksandr A. Siniaev, Vasily Shuvaev, Anastasia N. Vasileva, Lubov Gavrilova, Maria Grishunina, Kristina Zakurdaeva, Mikhail A. Kunst, Marina O. Popova, Vladimir I. Vorobyev, K D Kaplanov, Al'-Radi Ls, Andrei Petrenko, Yulia A. Chabaeva, Daria Baryshnikova, Vitaly S. Dubov
Publikováno v:
Clinical Lymphoma, Myeloma & Leukemia
Background Patients (pts) with lymphoproliferative diseases (LPD) are at high risk of COVID-19 severe and lethal course. Objective To evaluate treatment outcomes and risk factors in pts with LPD and COVID-19 in a real-world setting. Methods CHRONOS19
Autor:
Oksana Ochirova, Olga A. Gavrilina, Aleksandr A. Siniaev, Anastasia N. Vasileva, Yulia Sveshnikova, Sergei Dubov, Yulia A. Chabaeva, Marina O. Popova, Lev S. Butaev, Kaplanov Kd, Anzhelika F. Rakhmani, Inessa Yu. Toropova, Vitaly S. Dubov, Lubov Gavrilova, Mikhail A. Kunst, Alena Sukhareva, Valery G. Savchenko, Andrei Petrenko, Ekaterina Chelysheva, Kristina Zakurdaeva
Publikováno v:
Journal of Clinical Oncology. 39:e18715-e18715
e18715 Background: Pts with hem diseases are at high risk of COVID-19 severe course and mortality. Emerging data on risk factors and outcomes in this patient population is of great value for developing strategies of medical care. Methods: CHRONOS19 i
Autor:
Sergey M. Kulikov, Andrey N. Sokolov, A V Kokhno, T S Kaporskaya, Sergey A Makhinya, Yulia A. Chabaeva, Valery G. Savchenko, Larisa A. Kuzmina, Vera V. Troitskaya, Elena N. Parovichnikova, V A Lapin, Gennadiy M. Galstyan, G A Klyasova, Oleg A Latyshkevich, Olga A. Gavrilina
Publikováno v:
Leukemia Research. 104:106536
We report the data on 15 women who presented with Ph-negative acute lymphoblastic leukemia (ALL) between Jan 2009 until Dec 2016 and who were treated on the prospective multicenter RALL-2009 clinical trial. A comparison of their outcome was made with